Trazodone, Serum/Plasma
Also known as: TRAZO SP
Use
Trazodone is a selective serotonin reuptake inhibitor antidepressant drug indicated for the treatment of major depressive disorder. The pharmacokinetics of trazodone is influenced by drug-drug interactions that induce or inhibit CYP3A4 metabolism. Therapeutic drug monitoring is used to optimize drug therapy and monitor patient adherence. The test helps in managing adverse effects such as sedation, fatigue, headache, blurred vision, nausea, and cardiac arrhythmia, and addresses risks of serotonin syndrome when used with other serotonergic drugs.
Special Instructions
Not provided.
Limitations
The toxic range for trazodone is not well established, which may limit the ability to determine overdose levels through this test. The test has not been cleared or approved by the U.S. Food and Drug Administration and is developed by ARUP Laboratories as a Laboratory Developed Test (LDT) for use in a CLIA-certified facility. Drug-drug interactions affecting CYP3A4 metabolism can alter test results.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Trazodone
Analyte
LOINC Codes
- 4064-2 - traZODone SerPl-mCnc
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect in plain red, lavender (K2 or K3EDTA), or pink (K2EDTA) tube. Separate serum or plasma from cells within 2 hours.
Patient Preparation
Pre-dose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated transport.
Causes for Rejection
Whole blood and gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 2 weeks |
| Frozen | 4 months |
Other tests from different labs that may be relevant